Abstract
The use of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.
| Originalsprog | Engelsk |
|---|---|
| Titel | Clinical Nuclear Medicine in Neurology : An Atlas of Challenging Cases |
| Redaktører | Andrea Varrone, Silvia Morbelli, Valentina Garibotto |
| Antal sider | 5 |
| Udgivelsessted | Cham |
| Forlag | Springer International Publishing |
| Publikationsdato | 2022 |
| Sider | 119-123 |
| ISBN (Trykt) | 978-3-030-83598-9 |
| DOI | |
| Status | Udgivet - 2022 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Case 24: Progressive Glioma'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS